Marc Turner: VETERANSFirst, CHAMPION-AF Trial, and HI-PEITHO Trial Driving Innovation at ACC26
Marc Turner, SVP for US Corporate Accounts and Healthcare Solutions at Boston Scientific, shared on LinkedIn:
”ACC26 this past weekend put a spotlight on the progress happening across cardiovascular care.
The data was an important part of that, but so was the collaboration and effort behind it. For Boston Scientific, a few events especially stood out.
CHAMPION‑AF Trial
Adherence to anticoagulation remains a real-world challenge, and that can increase stroke risk for patients with non-valvular AF.
That is why the new CHAMPION-AF data presented at ACC and published in NEJM is so meaningful.
The CHAMPION‑AF trial met all primary and secondary safety and efficacy endpoints, studying WATCHMAN™ as a first‑line option for stroke risk reduction.
Pending regulatory, guideline, and coverage updates, these findings could triple the eligible WATCHMAN population and expand how we think about stroke risk reduction in AF.
Read the press release.
HI‑PEITHO Trial
EKOS Endovascular System plus anticoagulation (AC) demonstrated superiority to AC alone for the treatment of patients with intermediate-risk PE.
In urgent situations, every minute matters. It is great to see technology make a meaningful difference when clinicians need to act quickly and confidently.
Read the press release.
VETERANSFirst
One moment that particularly stood out at ACC 2026 was the first-ever VETERANS First Panel, which challenged us to think differently about AFib care for our nation’s Veterans.
In resource-strained environments, barriers like medication adherence, fall risk, limited staffing, anesthesia availability, and travel burden can make traditional care pathways difficult.
The panel’s message was clear.
When we think differently, we expand access to stroke risk reduction and become catalysts for innovation in AFib care delivery.
I’m proud of the teams behind this work and grateful for the trust our customers and clinical partners place in us.
There is still more to do, but weekends like this are a strong reminder of what is possible when innovation stays grounded in patient needs.”
Stay updated with Hemostasis Today.
-
Apr 4, 2026, 17:55Julian Kyoung-Ryul Chun: The Largest Dataset on Embolic Complications after AF Is Out
-
Apr 4, 2026, 17:54Marie Dragoy: Insights from Norway on Helicopter Emergency Services in Suspected Stroke Care
-
Apr 4, 2026, 17:53Julia Shapranova: Connecting Neuroscience with The Reality of Clinical Trials Leadership and Management at ESOC 2026
-
Apr 4, 2026, 17:51Filippo Cademartiri: The DECIDE Registry Tackles a Critical Gap In Cardiovascular Care
-
Apr 4, 2026, 17:51Rabiah Alnoshan: A Pactical, Bedside Focused Approach to Bleeding
-
Apr 4, 2026, 17:50Rob Maloney: How Our Camp Brings Relief to Children with Bleeding Disorders and Their Families
-
Apr 4, 2026, 16:11Shiny K. Kajal: Platelet Transfusion Is a Clinical Decision, Not a Reflex
-
Apr 4, 2026, 16:09Khaled Musallam: Revisiting Global Anemia Burden with Revised WHO Hemoglobin Criteria
-
Apr 4, 2026, 16:07Rabi Hanna: RUBY Trial Shows Life-Changing CRISPR Therapy for Sickle Cell Disease